Losartan Potassium Tab Usp 25mg (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)
Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-4007
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-4007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Spl Image1 Structure1)
Figure 1 (Spl Image2 Figure1)
This text provides information on a clinical study involving Atenolol and Losartan Potassium. It mentions the percentage of patients reaching the primary endpoint, an adjusted risk reduction of 13% with a p-value of 0.021. The timeline of the study is also indicated, with the months labeled from 0 to 66.*
Figure 2 (Spl Image3 Figure2)
This text provides information comparing the risk reduction of Atenolol and Losartan Potassium, with an adjusted risk reduction of 25% and a p-value of 0.001. It also shows the percentage of patients with fatal/non-fatal stroke across different study months from 6 to 66.*
Figure 3 (Spl Image4 Figure3)
This text provides data on primary endpoint events within demographic subgroups from a study comparing the efficacy of Losartan Potassium and Atenolol in preventing stroke (fatal/non-fatal). The demographic subgroups analyzed include age, gender, race, presence of isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). The results are presented in terms of event rates, hazard ratios, and confidence intervals. The study adjusted for baseline Framingham risk score and left ventricular hypertrophy levels. The sample sizes for each subgroup are represented proportionally by symbols.*
Figure 4 (Spl Image5 Figure4)
This is a graph showing the percentage of patients with an event over a period of 48 months for Losartan Potassium compared to a Placebo. The risk reduction is calculated to be 16.1% with a statistically significant p-value of 0.022.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
